John Maraganore

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Cambridge, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Troy Ignelzi, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for John Maraganore

Form 4 holding Chief Executive Officer, Director

ALNYLAM PHARMACEUTICALS, INC.

Security class
Common Stock
Shares / value
227,663
Estimated value
$42,190,507
Report date
22 Dec 2021
Price
$185.32
Ownership
Direct
Form 4 holding Chief Executive Officer, Director

ALNYLAM PHARMACEUTICALS, INC.

Security class
Common Stock
Shares / value
3,133
Estimated value
$580,608
Report date
21 Dec 2021
Price
$185.32
Ownership
by Managed Account
Form 4 holding Director

Beam Therapeutics Inc.

Security class
Stock Option (Right to Buy)
Shares / value
19,676
Estimated value
$563,982
Report date
03 Jun 2026
Price
$24.40
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Hemab Therapeutics Holdings, Inc.

Security class
Warrants (Right to Buy)
Shares / value
107,338
Estimated value
Report date
29 Jan 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Executive Officer, Director

ALNYLAM PHARMACEUTICALS, INC.

Security class
Stock Option (right to buy)
Shares / value
51,661
Estimated value
Report date
10 Dec 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

PROKIDNEY CORP.

Security class
Director stock option (right to buy)
Shares / value
48,128
Estimated value
Report date
29 Jun 2023
Price
Ownership
Direct
Underlying class
Class A Ordinary Shares
Underlying amount
Form 4 holding Director

Hemab Therapeutics Holdings, Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
04 May 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Hemab Therapeutics Holdings, Inc.

Security class
Series C Preferred Stock
Shares / value
0
Estimated value
Report date
04 May 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by John Maraganore

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .